+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Presbyopia Pipeline Drugs and Companies, 2021- Phase, Mechanism of Action, Route, Licensing/Collaboration, Pre-clinical and Clinical Trials

  • PDF Icon

    Report

  • 70 Pages
  • November 2021
  • Region: Global
  • VPA Research
  • ID: 5463891
Presbyopia pipeline drugs and companies, 2021- Phase, Mechanism of Action, Route, Licensing/collaboration, pre-clinical and clinical trials

The global comprehensive report on “Presbyopia pipeline drugs and companies” presents key-decision makers with critical insights into Presbyopia pipeline data. It provides complete analysis on pipeline drugs detailing Phases, route of administration, mechanism of action, licensing and collaborations, clinical trial details including pre-clinical phase and clinical trials.

Presbyopia pipeline Drug Snapshot, 2021


The Presbyopia pipeline study analyzes and monitors the development landscape with the current status of each of the pipeline drugs under development for Presbyopia. In addition to recent status, overview of drugs is included in the study. Wide range of Presbyopia drug related details including of company, indication, country, current status, drug alternative names, originator, orphan drug status, fast track details and others are provided.

Presbyopia drug development pipeline by phase


The Presbyopia pipeline study monitors the progress of new drug programs and provides analysis of phases, covering drugs from discovery to launch including discovery stage, preclinical, phase 1, phase 2, phase 3, pre-registration and other phases. The drug development stage for all Presbyopia pipeline candidates is provided in the report enables you to understand timetable developments in Presbyopia therapeutic area.

Presbyopia pipeline drug Technology, Licensing and Collaboration Details


Details of technologies used for development of Presbyopia pipeline candidates, licensing and collaboration agreements, partnership and other announcements, regulatory approval and other details are included in the Presbyopia research study. Companies looking to partner with other players are also detailed in the report.

Presbyopia- mechanism of action of pipeline candidates


Presbyopia pipeline guide details the mechanism of action of each of the drug candidate under development. Further, leading types of mechanism of action (MoA) targeted by different Presbyopia companies are identified to support decision makers target the most potential drugs under development.

Further, route of administration including oral, topical, sub-cutaneous, IV, ophthalmic and others are provided to assist researchers to understand most sought and least sought route of Presbyopia drug administration.

Presbyopia Drugs- Preclinical and Clinical Trials


This chapter in Presbyopia preclinical and clinical trials assists in gaining clear understanding of the timetable developments in Presbyopia product area. Preclinical and clinical trial details of pipeline candidates for Presbyopia are detailed in the report. Details including participants, duration, companies, locations and others are provided for the trials.

Presbyopia companies and Profiles


Companies developing Presbyopia pipeline products are analyzed in the industry report, presenting details of business overview, location, and year of establishment, contacts, key employees, and a brief business profile.

Presbyopia Market Developments


The report presents the recent news and developments in the Presbyopia pipeline industry. Progress of candidates, mergers, acquisitions, asset transactions, licensing, collaborations, partnership and joint ventures, regulatory approvals, marketing and other relevant news and deals are discussed in the report.

Reasons to Buy

  • Make better-informed decisions based on the current status of each of the pipeline drug candidate
  • Identify new business opportunities by evaluating the progress of the Presbyopia R&D pipeline
  • Analyze the market and research segments based on a comprehensive analysis of Presbyopia pipeline drugs and clinical trials
  • Identify Presbyopia drug pipeline trends based on consistently delivered hands on pipeline and clinical trials information
  • Gain clear understanding of the Presbyopia drugs through our expert coverage and in-depth analysis of drugs, companies and market trends
  • Check the Presbyopia pipeline progress of target companies and key strategies of leading players
  • Gain real-time insights into the global Presbyopia pipeline news, developments and insights

Scope of the Report

  • Disease overview including Presbyopia symptoms, widely used treatment options, companies and other details are included
  • Presbyopia Pipeline Summary including the dominant phase type, number of drug candidates progressing to advanced phases, early stage pipeline candidates, leading companies, dominant route of mechanism and route of administration and other details are provided.
  • Presbyopia pipeline drug count by phase, company and mechanism of action
  • Presbyopia companies investing R&D resources in pipeline
  • Dominant Mechanism of Action
  • Most researched route of administration
  • For each pipeline candidate, drug, originator, co-developers, other companies, special status, phase, synonym, current status and other details are included
  • Clinical trial information for each Presbyopia pipeline candidate are provided including preclinical, phase 1, phase 2 and phase 3 details
  • Presbyopia companies including their business snapshot, business description and Presbyopia pipelines are included.
  • Recent Presbyopia market developments, pipeline news and deals are provided

Table of Contents

1. Table of Contents
1.1 List of Tables
1.2 List of Figures
2. Executive Summary
2.1 Presbyopia Disease overview
2.2 Companies investing in Presbyopia industry
3 Presbyopia Pipeline Snapshot, 2021
3.1 Presbyopia Pipeline Drugs- Dominant phase type
3.2 Presbyopia pipeline Drugs- Leading Mechanism of Action
3.3 Presbyopia Pipeline Drugs- Widely researched Route of Administration
3.4 Presbyopia Pipeline- New Molecular Entity
3.5 Presbyopia pipeline- Companies, Universities and Institutes
4. Presbyopia Drug Profiles
4.1 Current Status of Presbyopia Drug Candidates, 2021
4.2 Presbyopia Drugs in Development- Originator/Licensor
4.3 Presbyopia Drugs in Development- Route of Administration
4.4 Presbyopia Drugs in Development- New Molecular Entity (NME)
5. Presbyopia Clinical Trials
5.1 Preclinical Trial details
5.2 Phase 1 Clinical Trial Details
5.3 Phase 2 Clinical Trial Details
5.4 Phase 3 Clinical Trial Details
6. Presbyopia Companies and Universities
6.1 Leading Presbyopia companies researching in drug development
6.2 Leading Presbyopia Universities/Institutes investing in drug development
7. Presbyopia News and Deals
7.1 Recent Presbyopia Market Developments
7.2 Pipeline Drug News Updates
7.3 Pipeline Company updates
8. Appendix
8.1 Sources and Research Methodology
8.2 Online Database
8.3 Primary and Secondary Methodology
8.4 Customization options
8.5 Contact